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 ABSTRACT
Alloantibodies against donor human leukocyte antigens (HLA), termed as donor -specific antibodies (DSA), are 
one of the most important factors for both early and late kidney allograft dysfunction. In the past, these antibod-
ies were mainly detected through cell -based crossmatch tests. Recently, new techniques such as solid phase 
immunoassays (SPI) have revealed these antibodies in patient sera with a high degree of detail, previously 
unimaginable. They have allowed us to accurately determine recipients’ allosensitization status, improve pre-
-transplant risk assessment with a potential donor and post -transplant alloimmune monitoring. However, the 
high sensitivity of these new assays has also created areas of uncertainty about their clinical impact.
In the pre -transplant setting, the presence of preformed DSA has been associated with an increased risk of 
antibody -mediated rejection (AMR) and subsequent allograft loss. Nevertheless, several studies have shown that 
not all DSA are deleterious. Hence, understanding the clinical correlations of DSA characteristics, namely strength, 
HLA class, complement -fixing ability or IgG subclasses, is paramount for an adequate stratification of the immu-
nological risk at transplant. Furthermore, given that the number of allosensitized patients on waiting lists is 
increasing, the added information from these new SPI is essential to improve their chance of being transplanted 
with an admissible immunological risk.
After transplantation, the appearance of de novo DSA (dnDSA) has also been associated with a deleterious 
effect on kidney allograft survival. Moreover, it has been acknowledged that a majority of late allograft failures 
are caused by alloantibody -driven injury. The current challenges, in this setting, are determining cost -effective 
DSA screening protocols and understanding which patients could benefit from specific interventions. Furthermore, 
although therapeutic strategies to control antibody -induced damage remain limited, the longitudinal surveillance 
of dnDSA emergence and the clinical correlations of their characteristics will play a crucial role in the improve-
ment of late kidney allograft survival.
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 INTRODUCTION
Despite improvements in patient selection and 
management, most transplants carry some immuno-
logical risk. Alloantibodies against human leukocyte 
antigens (HLA), chiefly donor -specific antibodies 
(DSA), either present at the time of transplantation 
or arising de novo post -transplant, are a risk factor 
for antibody mediated rejection (AMR) and potentially 
kidney allograft loss1. Hence, avoiding DSA at trans-
plant is a desirable objective, although not always 
possible to attain, particularly in highly -sensitized (HS) 
patients. Moreover, it has been demonstrated that 
patient survival is improved with HLA -incompatible 
Port J Nephrol Hypert 2018; 32(1): 42-51    43
kidney transplantation together with desensitization 
strategies in comparison to waiting on dialysis for a 
HLA -compatible allograft2.
Our aims in this review are to provide a practical 
guide for using solid phase immunoassays (SPI) and 
crossmatch (XM) testing, either before or after kidney 
transplantation, and to contribute to a better under-
standing of their clinical implications.
 TECHNICAL ASPECTS
Kidney transplantation (KT) requires a thorough 
immunological study between donor and recipient pair 
(Table 1). 
 HLA Typing
HLA typing was first performed by lymphocytotoxic 
assays3 but since polymerase -chain -reaction (PCR) 
description in 19904, molecular methods have improved 
greatly and performing HLA typing at the antigen level 
for HLA -A,  -B and –DRB1 loci is now mandatory for all 
donors and recipients pairs. Extended typing for HLA -C, 
 -DQ and/or –DP should also be performed to assess 
complete degree of matching between the pair, espe-
cially if the recipient has alloantibodies against any of 
these loci.
The methods employed are sequence -specific-
-primer (SSP)5, real -time PCR (qPCR), reverse sequence-
-specific oligonucleotide (rSSO)6 and sequence -based 
typing (SBT)7. The choice of the method depends on 
the resolution needed, how urgent the need for the 
results is and the number of samples to process.
Recently, a new technology of next generation 
sequencing (NGS) has been introduced in histocompatibil-
ity laboratories, allowing allelic level typing with high 
throughput8, an improvement still controversial9. 
Although it would allow better HLA matching, with an 
indisputable role in reducing sensitization, improving 
allograft survival10, and clearly benefiting sensitized 
patients11, it would also prevent transplants offers for 
rare alleles due to the high polymorphism of HLA region12.
Understanding that transplanting all patients with 
a HLA full -match allograft is an impossible goal, and 
that HLA mismatches are inevitable, it is our task to 
minimize their impact. In this context, the future for 
organ allocation systems can be HLA eplet matching 
by electing transplants with low HLA eplet mismatch 
(MM) load and avoiding highly immunogenic eplets13.
Besides matching, HLA typing is of extreme impor-
tance when performing the virtual crossmatch (vXM) 
at an organ offer (Table 1). A vXM is positive when a 
patient has HLA alloantibodies against a particular 
donor, i.e. DSA. A positive vXM usually is a contra-
-indication for transplant but, depending on the locus 
involved, alloantibody strength, patient immunological 
history and sensitization status, it can be considered 
as a risk factor with appropriate immunosuppression 
strategies2,14.
 Allosensitization status
About 25–35% of patients on the waiting list for KT 
are pre -sensitized15, mainly due to previous trans-
plants, followed by pregnancies and transfusions16. 
While on the waiting list, KT candidates must undergo 
alloantibody testing every three months and after each 
sensitizing event, with cellular and SPI (Table 1).
Cellular assays
Cellular assays are crossmatch tests between donor 
lymphocytes and recipient sera. To accomplish this, 
viable donor lymphocyte isolation is required, usually 
performed by density gradient centrifugation17. More 
recently, lymphocyte isolation with magnetic beads has 
been introduced with considerable improved results18.
Table 1
Kidney transplant candidates’ laboratory assays*
Pre -transplant On the waiting list
HLA antigen typing
Anti -HLA antibodies screening with CDC & PRA -CDC#
Anti -HLA antibodies screening with SPI#
Anti -HLA antibodies identification with SAB, UA assign-
ment & cPRA§
Pre -transplant At an organ offer 
Virtual crossmatch
CDC crossmatch
Flow cytometry crossmatch in allosensitized patients
Post -transplant Transplant recipient 
Anti -HLA antibodies screening with SPI
Anti -HLA antibodies identification with SAB, to assess if 
DSA are present
CDC – complement -dependent -cytotoxicity; PRA – panel reactive antibodies; SPI – solid-
-phase immunoassays; SAB – single -antigen beads; UA – unacceptable antigens; cPRA 
– calculated PRA; DSA – donor -specific antibodies.
* According to Circular Normativa nº1/DQS de 07/01/09 da Direção Geral da Saúde.
# Performed every three months until transplant.
§ Performed annually until transplant.
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Cell -based crossmatches include complement-
-dependent cytotoxicity (CDC) and flow cytometry 
crossmatch (FCXM).
Cytotoxic Crossmatch
CDC crossmatch (CDC -XM) was first described by 
Terasaki and Patel in 196919. They showed that the 
presence of alloantibodies in recipient sera against 
antigens expressed on donor lymphocytes was a major 
risk factor for immediate allograft loss.
The assay consists of a first incubation (30 minutes) 
of recipient sera and donor cells in a micro -well tray 
allowing, if present, DSA binding to donor cells. It can 
be performed from total lymphocyte population or 
after T - and B -lymphocytes sub -populations separation. 
Complement is then added following a second incuba-
tion (60 minutes), activating the complement classical 
pathway, resulting in lymphocyte lysis. The cell mem-
brane loss of integrity is visualized with an inverted 
fluorescence microscope, after the addition of a vital 
dye. Percentage of cell lysis is recorded using the 
accepted International Histocompatibility Workshop 
(IHW) scoring system (0,1,2,4,6,8).
This methodology, called National Institute of Health 
(NIH) basic, standard or classic CDC -XM, detects the 
presence of IgG1, IgG3 and IgM cytotoxic alloantibodies 
and is performed at an organ offer (Table 1), reducing 
hyperacute and early accelerated rejection episodes. 
However, it has also been reported that some patients 
experienced early allograft loss despite a negative CDC-
-XM. To overcome this, several changes to the original 
technique were proposed to improve sensitivity, such 
as extended incubation times20, washing steps following 
first incubation removing unbound sera before adding 
the complement21, or amplifying complement activa-
tion and cell lysis with anti -human globulin (AHG)22. 
Nevertheless, these assays are also associated with false 
positive results due to clinically irrelevant non -HLA anti-
bodies and HLA IgM alloantibodies. The latter are fre-
quent in patients with autoimmune disorders and can 
be overcome by treating recipient’s sera with dithiothrei-
tol (DTT), reducing IgM disulfide bonds23. Also, autoreac-
tive cytotoxic alloantibodies can generate a positive 
irrelevant CDC -XM. In these cases, to assist the interpre-
tation of the allo -XM, an auto -XM is recommended24.
Flow Cytometry Crossmatch
Despite all uplifts in the classic CDC -XM technique, 
it was only with FCXM that a true sensitivity boost was 
seen in cellular assays, allowing the detection of low 
level DSA25. For this reason, a positive FCXM with a 
negative CDC -XM does not predict hyperacute rejec-
tion, but a lower allograft survival at 1 -year20. This assay 
is performed at an organ offer for every sensitized 
patient and in most living donations (Table 1).
This methodology detects non -complement fixing 
alloantibodies and was first described by Garovoy et 
al26. In 1989, Bray et al. described a dual -color meth-
od27 and in 1996 a three -color method was described 
by Robson et al.28. This assay consists of an indirect 
immunostaining where antibody -antigen interaction is 
identified using an anti -human immunoglobulin (F(ab’)2 
anti -IgG) labeled with a fluorochrome. T - and B - lym-
phocyte subpopulations are identified using the mono-
clonal alloantibodies anti -CD3 and anti -CD19, labeled 
with fluorochromes with different emission wave-
lengths. A positive reaction is calculated based on the 
median channel shift (MCS) between negative controls 
and patient sample using a cut -off value established 
within each laboratory.
This technique has also been a subject of different 
improvements, with Lobo et al.29 describing that pro-
nase treatment of the cells, prior to the FCXM assay, 
increased sensitivity and specificity30. It has also been 
shown that this treatment is effective in eliminating 
rituximab interference used for desensitization31.
Recently Liwski et al. investigated the impact of sev-
eral assay parameters, such as incubation times and 
temperatures, cell number per reaction and serum:cell 
suspension volume ratio, developing of a rapid FCXM 
procedure: the Halifax and Halifaster protocols18. The 
Canadian group optimized protocols allow cost reduc-
tion with decreased assay time, without compromising 
sensitivity.
Solid ‑phase immunoassays
SPI consist of solid -phase platforms with purified 
HLA antigens covalently bound, such as the wells of a 
polystyrene microplates or microspheres. These tests 
are performed every three months before transplant, 
but also after transplantation ideally after the first, 
third, sixth month and then annually (Table 1).
ELISA
Enzyme -linked immunosorbent assays (ELISA) has 
been described by several authors as an alternative 
method to cell -based assays32. Soluble HLA (sHLA) 
antigens are affixed to the wells of microtiter plates. 
HLA specific alloantibodies present in patient sera will 
bind to HLA antigen after being added to the well. This 
antibody -antigen interaction is detected by the 
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addition of an alkaline phosphatase -conjugated with 
anti -human immunoglobulin (IgG) antibody. A quan-
titative measure of the extent of reaction is obtained 
by spectrophotometric determination following the 
addition of the appropriate enzyme substrate for the 
color development.
Multi -analyte profiling (xMAP®) technology
xMAP® technology is a multiplex assay that uses a 
panel of fluorescently dyed micron -sized polystyrene 
microspheres, produced by the internal conjugation of 
variable amounts of two or three dyes, enabling the 
identification of 100 or 500 different beads, respec-
tively. HLA antigens are bound to these coded -color 
beads and, after a first incubation with patient’s sera, 
any HLA alloantibodies present bind to the antigens on 
the beads. This reaction is detected, after a second 
incubation with R -Phycoerythrin (PE) -conjugated goat 
anti -human IgG, with a Luminex® flow analyzer (LAB-
Scan™ 100 or LABScan3D™) that simultaneously detects 
the fluorescent emission of PE and the dye signature 
from each bead. The light signal produced by bound is 
proportional to its concentration and is expressed as 
the mean fluorescence intensity (MFI).
The first xMAP® assay described used beads coated 
with HLA proteins extracted from individuals’ cells, 
allowing improved standardization in HLA alloantibod-
ies detection. These beads can be composed by a 
pooled antigen panel – screening assay –33 or by a 
single individual cell line – phenotypic assays34. 
Although a substantial improvement was brought to 
histocompatibility laboratories by these assays, it was 
still difficult to assign alloantibody specificity, especially 
for highly sensitized patients. To surpass this limitation, 
the same group published a modification of the assay 
that revolutionized allosensitization assessment35. This 
improved method consists of coated beads with a single 
class I or class II HLA recombinant antigen; the single 
antigen bead (SAB) assay. Since then, SAB has been the 
method of choice for unacceptable HLA antigen assign-
ment in patients on the waiting list for deceased donor 
kidney transplantation, although the cut -off value for 
positivity definition has been a challenge. Despite the 
1000–1500 MFI value is usually taken into considera-
tion, we must not forget that this is a semi -quantitative 
assay and epitope and cross -reactive groups (CREG) 
should be considered in the analysis36.
Classic SAB assay detects anti -HLA alloantibodies of 
all IgG subclasses, but they are not equally detrimental. 
To address this issue, a modification of the standard 
SAB IgG method to detect only complement -binding 
HLA alloantibodies was developed37. In this test, human 
complement C1q is added in the first incubation with 
patient sera and HLA -coated beads. The HLA alloanti-
bodies bind to the target antigens, followed by attach-
ment of C1q to alloantibodies that are complement-
-binding. An anti -human C1q, conjugated with PE, is 
used as a reporter to indicate the presence of 
complement -binding HLA alloantibodies when analyzed 
in a Luminex® instrument. Another assay to detect 
complement -binding HLA alloantibodies was recently 
introduced into the market. This newest test uses an 
anti -human C3d antibody, thus analyzing a different 
downstream step of the classic complement pathway 
than the former C1q assay38.
Although a certain degree of correlation between 
the amount of alloantibody and complement -fixing 
activation should be expected, as at least six alloanti-
bodies organized in hexamer are necessary to initiate 
the complement cascade39, the added value of this 
assay is debatable within the transplantation commu-
nity. Several authors have suggested that this assay 
might be redundant when compared to the MFI value 
in the classic IgG SAB assay, especially if confounding 
analytical interferences are corrected40.
Interpretative considerations
Although cellular assays are of undeniable impor-
tance, one should also understand their limitations. All 
cell -based assays can give misleading results: false 
positivity, due to autoantibodies and non -HLA antibod-
ies, and false negatives as a result of their lack of sen-
sitivity for low titer alloantibodies.
With the newer SPI methods, laboratories intended 
to overcome these deficiencies. This technology proved 
to have several advantages over classic methods such 
as: i) elimination of the necessity for viable lympho-
cytes, allowing automation and becoming a high-
-throughput laboratory method; ii) consistent and 
extended HLA panel, ensuring HLA antigen representa-
tiveness; iii) sensitivity, detecting low titer alloantibod-
ies; iv) specificity, detecting only HLA IgG alloantibodies 
and v) clear distinction between HLA class I and class 
II alloantibodies (Table 2).
However, regardless of SPI assays’ unquestionable 
utility, in particular SAB assays that allow a greater 
accuracy in unacceptable HLA antigen assignment and 
the introduction of calculated panel reactive antibodies 
(cPRA), it is very important to understand that this 
methodology also has important limitations. SAB have 
limited HLA alleles, antigen density variations and 
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cryptic epitopes exposure, resulting in false positivity 
due to denatured antigens42. This laboratory assay is 
also affected by immunomodulatory treatments such 
as intravenous immunoglobulin, resulting in increased 
background43, and ATG treatment, where usually an 
HLA -A3 is identified because it is a polyclonal rabbit 
antibody raised against the Jurkat human T -cell line 
(HLA -A3, 32; B7, 35)44. It also suffers from complement 
activating alloantibodies interferences that deposit C1 
complex on the beads, or IgM alloantibodies, interfer-
ing with secondary antibody binding giving false nega-
tive results, called prozone effect. Several changes have 
been proposed in order to upgrade the test, such as 
dilutions, EDTA (ethylenediaminetetraacetic acid), DTT 
or heat treatment45.
All methods available should be considered in an 
integrated analysis (Table 3), along with history of 
sensitization, understanding that all techniques have 
different levels of sensitivity, detect different types 
of alloantibodies, and are subject to different inter-
ferences46. As such, the decision to proceed with a 
KT should be the result of a multidisciplinary team 
effort between clinicians and histocompatibility labo-
ratory to ensure the best immunological evaluation 
possible.
Table 2
Cellular vs. microspheres solid -phase assays, advantages and disadvantages.
Immunoassays
Cellular based Microspheres solid -phase
CDC FCXM Screening Phenotypic Single -antigen
Antigen source Ly Ly Cell -line pool Cell -line Rec allele
Antigen density ++ ++ + ++ +++
Sensitivity + ++ ++ ++ +++
Viable cells Yes Yes No No No
Allows Ab identification Yes* No No Yes* Yes
HLA class I & II Ab No No Yes Yes Yes
C’ fixing Ab Yes No No No Yes#
Auto -Ab Yes Yes No No No
IgM Ab Yes No No No No
Denaturated Ab No No No No Yes
Prozone (C’) interference No No No No Yes
CDC – Complement -dependent -cytotoxicity; FCXM – Flow cytometry crossmatch; Ly – Lymphocyte; Rec – Recombinant; Ab – antibody; C’ – Complement.
*Yes, but with limitations in high sensitized patients.
#Yes, with C1q or C3d assays.
Adapted from reference 41.
Table 3
Interpretation of cellular vs. single -antigen bead immunoassay.
CDC LyT CDC LyB FCXM LyT FCXM LyB
SAB
HLA class I
SAB
HLA class II
Interpretation
POS POS POS POS + + HLA class I & class II Ab
POS POS POS POS +  - HLA class I Ab
NEG POS POS POS + + ↓HLA class I Ab & class II Ab
NEG NEG POS NEG +  -  - low expression Ab (HLA -Cw)
NEG POS POS POS +  - ↓ HLA class I Ab
NEG NEG POS POS +  - ↓↓HLA class I Ab
NEG POS NEG POS  - + HLA class II Ab
NEG NEG NEG POS  - + ↓ HLA class II Ab
NEG NEG POS NEG  -  - pronase interference in FCXM
POS POS POS POS  -  - non -HLA Ab
POS POS NEG NEG  -  - IgM Ab
NEG NEG NEG NEG  -  - no Ab detected
CDC – Complement ‑dependent ‑cytotoxicity; FCXM – Flow cytometry crossmatch; SAB – Single ‑antigen ‑bead; Ly – Lymphocyte; Ab – antibody; ↓ – low titer; ↓↓ – very low titer.
Adapted from reference 41.
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  WAITLIST TESTING OF ANTI ‑HLA 
ANTIBODIES
As described in Table 1, KT candidates in waitlist are 
tested quarterly, or after any sensitizing event, to assess 
allosensitization degree with panel reactive antibodies 
(PRA) value, and to assign unacceptable antigens (UA) 
for virtual crossmatch (vXM).
 Defining unacceptable antigens
UA are assigned by SAB, using a reference cut -off 
that is usually 1000 MFI, and by CDC. The definition of 
UA for all wait -listed patients allows vXM determination, 
a preliminary in silico crossmatch that predicts positive 
crossmatches. The usefulness of this step is to avoid 
performing crossmatches that will be positive, although 
this is not an absolute contraindication per se.
 Measuring transplantability
PRA is a measure of patient’s degree of sensitization 
while on the waiting list for transplantation, representing 
the percentage of the population to which the patient 
is sensitized47. Traditionally, it was performed by CDC 
using a panel of HLA typed donors, allowing the identi-
fication of UA, although with a high degree of inaccuracy 
since each cell expresses six alleles. A candidate for kid-
ney transplantation with a PRA>85% is considered HS 
and usually is prioritized in allocation programs.
This classic PRA value depends greatly in the panel 
composition, that may not represent the antigen fre-
quencies in the donor population, besides the fact that 
rare antigens are usually missed in the panel, and CDC 
intrinsic low sensitivity. For this reason, PRA does not 
provide an accurate measure of transplantability and, 
with the development of SAB assays, cPRA was intro-
duced providing consistency48. Nowadays cPRA has 
replaced classic PRA in most kidney allocation systems 
worldwide, with great improvements in transplantation 
rates for sensitized patients49.
  STRATIFYING THE RISK  
OF PREFORMED DSA
Several centers have a sizeable experience in per-
forming kidney transplants in the presence of pre-
formed DSA, in which the potential risk of AMR is 
considered acceptable14,50,51. They base their approach 
on the knowledge that not all DSA are equally patho-
genic, with some of them being manageable through 
the use of increased immunosuppression or desensi-
tization protocols. Hence, understanding DSA charac-
teristics, namely strength (read as MFI), HLA class, 
complement -fixing ability or IgG subclasses, is para-
mount for an adequate stratification of the immuno-
logical risk at transplant.
 DSA strength
Although SAB assay was not approved as quantita-
tive, it has been used clinically as a semiquantitative 
assay for the estimation of a given anti -HLA alloantibody 
strength (measured as MFI). Several groups have shown 
that a higher DSA MFI is associated with AMR and allo-
graft loss52-54.
Frequently, patients present at transplant with more 
than one DSA. So, determining if DSA strength measure-
ment should consider the immunodominant DSA (high-
est MFI) or the MFI sum of all detected DSA (cumulative 
MFI) is an important, though still unanswered question. 
Many centers opt to use one of them, since the com-
parison of their predicted behavior has not produced 
a clear result54,55. Recently, Zecher et al.53 showed, in 
non -desensitized patients, that only DSA MFI above 
10000 (immunodominant or cumulative) were associ-
ated with AMR occurrence and reduced allograft sur-
vival. Our group has demonstrated that DSA strength 
had a good predictive performance for AMR occurrence, 
with a MFI >5000 in the immunodominant DSA having 
a sensitivity of 86% and a specificity of 73%55. Impor-
tantly, in our cohort, preformed DSA were associated 
with reduced kidney allograft survival only when AMR 
occurred. Similar results have been published by other 
groups52,54,56,57, although the MFI threshold to define 
DSA as clinically significant varied between 3000 and 
10000 according to DSA number, HLA loci or the use of 
desensitization, limiting the reproducibility of these 
results. Alternatively, considering the pivotal role of HLA 
laboratory protocols, each center should work with their 
reference lab to define in -house clinically significant DSA 
MFI thresholds. Furthermore, the full extent of the data 
given by SAB assays must be integrated with other vari-
ables, such as past sensitization events, the immunosup-
pression or desensitization used and the results of cell-
-based crossmatches, namely flow cytometry58.
An alternative to DSA MFI, as a measure of alloan-
tibody strength, is the determination of its titer, in 
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which serial dilutions are performed until the alloan-
tibody is no longer detected, corresponding that dilu-
tion to the alloantibody titer40. This approach is inher-
ently closer not only to the alloantibody strength but 
also to its avidity, pertaining a closer representation of 
the in vivo antibody pathogenicity. Nevertheless, the 
clinical application of alloantibody titration in kidney 
transplantation remains largely undetermined and the 
high cost and labor involved prevents, at the moment, 
its broader use59.
 DSA HLA class
Historically, it was considered that DSA against HLA 
class I was chiefly associated with early immunological 
events, while DSA against HLA class II were more impor-
tant in the development of late (chronic) rejection60. 
When detailed analyses of DSA by solid -phase assays 
became available, published data demonstrated that 
both classes are equally pathogenic54. Moreover, DSA 
against HLA -Cw,  -DQ or  -DP, previously underappreci-
ated, have shown to be responsible for the develop-
ment of acute or chronic AMR and should be taken 
into account (61, 62). Likewise, different groups have 
reported that the presence of DSA against both HLA 
classes poses a significantly higher risk of AMR and 
allograft failure52.
 Complement ‑binding DSA
The activation of complement is an important step in 
DSA -driven allograft injury, starting with C1q binding and, 
downstream, C3 cleavage and production of C3d38. Modi-
fied SAB assays have been produced to detect DSA C1q - or 
C3d -fixing ability63. Several studies have analyzed 
complement -activating DSA ability correlation with its 
pathogenicity, with no clear -cut results. Some demon-
strated a strong association between C1q - or C3d -binding 
DSA, AMR and allograft failure64,65, while others did 
not66,67. In the setting of preformed DSA, our group68 
found that C1q and IgG MFI were both correlated with 
AMR. C1q status was better than IgG DSA strength of at 
least 15 000 MFI (OR=16.3 vs. 6.4, respectively) for predict-
ing AMR. Furthermore, C1q+ DSA was a significant risk 
factor for AMR (OR = 16.80, P = 0.001) but high MFI DSA 
was not. Six -year allograft survival was also significantly 
lower in high MFI C1q+ DSA in comparison with high MFI 
C1q−, or low MFI DSA (38, 83 and 80%, respectively; 
P = 0.001). Recently, similar results have been reported69. 
However, an important drawback of these assays is their 
close relationship with DSA MFI and titer, limiting our 
ability in distinguishing the negative effects of complement-
-activating DSA from its MFI70. Moreover, a large study 
has reported that C1q+ DSA was not associated with allo-
graft failure when present only before transplant64.
 DETAILING THE RISK OF DE NOVO DSA
Some of the observations referred above in relation 
to preformed DSA should be taken into account when 
analyzing the risk of de novo DSA (dnDSA), although 
the specificities of the latter merit a closer look of clini-
cal data in this setting. One issue that remains under 
discussion is the timeframe of dnDSA detection post-
-transplant. International guidelines published in 2013 
(Table 4) indicate that, in the first -year post -transplant, 
all patients should undergo DSA screening at 3 - and 
12 -months, besides other clinically -driven indications71. 
A more intense screening schedule is proposed for 
patients with higher immunological risk (e.g., those 
desensitized). After 1 -year, they recommend the stor-
age of serum every year, with DSA detection being 
performed when clinically indicated.
 Incidence and clinical impact of de novo DSA
The negative impact of dnDSA on long -term kidney 
allograft survival is widely recognized72. Moreover, when 
analyzing the causes of allograft failure, the Deterioration 
of Kidney Allograft Function (DeKAF) study showed that 
Table 4
Laboratory assays after kidney transplantation – consensus guidelines71
Post -transplant (0 -12 months)
Very high risk (desensitized patients)
 DSA monitoring and protocol biopsy within the first three months.
High risk (vXM positive & negative CDC -XM)
 DSA monitoring and protocol biopsy within the first three months.
Intermediate risk (historical positive vXM or CDC -XM)
 DSA monitoring within the first month, if negative follow -up as low risk.
Low risk
  DSA screening at least once between the third and twelve months after 
KT and if significant changes in IS, suspicion of non -adherence, graft dys-
function or if transferred to another center.
Post -transplant (after the first year)
Every risk categories
 Store at least one serum per year
  DSA screening in a current serum if significant changes in IS, suspicion of 
non -adherence, graft dysfunction or transferal to another center.
DSA – donor -specific antibodies; vXM – virtual crossmatch; CDC -XM – complement-
-dependent -cytotoxicity crossmatch; KT – kidney transplant; IS – immunosuppression.
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a majority of them was caused by rejection (64%), chiefly 
antibody -mediated73. Recently, in a case -control study, 
we reported74 that DSA prevalence in patients with allo-
graft failure (cases) was 56%, while only 16% in those 
remaining with a functioning allograft (controls).
Several recent longitudinal studies have detailed the 
role of dnDSA in allograft loss75,76. In previously non-
-sensitized kidney allograft recipients, incidence of 
dnDSA at 1 -year was 11%, with an increase to around 
20% at 5 -years76. Wiebe et al.75 documented dnDSA 
in 15% of low -risk patients at 4.6±3 years post-
-transplant, with a 10 -year allograft survival of 57% in 
those with dnDSA and 96% in those without dnDSA. 
Importantly, they also demonstrated that non-
-adherence was the most important risk factor for de 
dnDSA emergence (OR=8.75, P<0.001). In a cohort of 
simultaneous pancreas -kidney transplanted patients, 
we showed77 that dnDSA were detected in 15% at a 
median 3.1 years after transplant. dnDSA were signifi-
cantly associated with kidney (in association with acute 
rejection) and pancreas allograft failure.
 Clinical correlations of de novo DSA characteristics
DSA strength
Data on the impact of alloantibody MFI on allograft 
outcomes in the setting of dnDSA is scarcer than in 
preformed DSA. Recently, a longitudinal study analyzing 
the rates of progression to allograft failure in patients 
with dnDSA, showed that DSA MFI was an independent 
predictor of failure (HR per 1000 MFI=1.02, P=0.029)78. 
Heilman et al. observed that cumulative incidence of 
AMR or mixed rejection at 1 year was 30% in the group 
with dnDSA MFI >3000 but only 4% for the group with 
a MFI <300079. Others have shown that dnDSA MFI 
levels were associated with higher rate of acute AMR 
but did not have a significant impact on allograft 
survival80.
DSA HLA class
One of the striking observations, when studying 
dnDSA, is the clear predominance of antibodies against 
HLA class II. Wiebe et al.75 reported, in 47 patients 
dnDSA, that DSA anti -HLA class I only were present in 
3 patients, while 32 had anti -HLA class II only and the 
remaining 12 had DSA against both HLA classes. Others 
also observed a more frequent detection of dnDSA 
against class II (77%) than against class I (38%) HLA 
antigens76. In this study, class I alloantibodies made up 
42% of early DSA (< 6 months after transplantation) 
but were only 29% of late DSA (> 6 months after 
transplantation). Conversely, class II was 58% of early 
DSA and 71% of late DSA. Importantly, no difference 
on allograft survival was observed comparing patients 
with dnDSA according to HLA class.
Another important observation reported by several 
studies is the high incidence of anti -DQ dnDSA. In the 
referred cohort by Wiebe at al.75, out of 44 patients with 
class II DSA, 31 had anti -DQ, while 21 had anti -DR DSA. 
Additionally, when they analyzed donor -recipient HLA -DR 
and  -DQ matching at epitope level, higher epitope mis-
match was significantly associated with dnDSA emer-
gence against the respective locus81. More recently, they 
expanded these observations showing that non-
-adherence and higher epitope mismatch acted syner-
gistically towards a higher risk of rejection or allograft 
loss82. Hence, the evaluation of patients’ adherence and 
epitope mismatch load are valuable tools in the identi-
fication of patients that could benefit from increased 
clinical, histologic and immunological surveillance.
Complement ‑binding DSA
Modified SAB assays analyzing complement binding 
DSA ability (C1q - and C3d -SAB) have been applied 
widely in the post -transplant setting63. A large study 
examining the impact of C1q -binding DSA on kidney 
transplantation, reported that C1q+ DSA, when present 
in the first year after transplantation were associated 
with a higher risk of allograft loss (HR=4.78, P<0.001)64. 
These alloantibodies were also associated with an 
increased rate of AMR, a more extensive microvascular 
inflammation, and increased deposition of C4d within 
allograft capillaries. Others have demonstrated that 
presence of C3d -binding DSA at the time of AMR diag-
nosis (HR=2.80, P=0.03) was an independent predictor 
of allograft loss65. More recently, Guidicelli et al.83 
observed that C1q -binding dnDSA were associated with 
allograft loss occurring rapidly after their appearance. 
However, the long -term persistence of C1q -nonbinding 
dnDSA also led to lower allograft survival, though in a 
more protracted manner.
These results raised great expectations in the trans-
plant community, that these modified SAB assays could 
allow the identification of patients with dnDSA at a 
higher risk of allograft failure, and in whom specific 
treatments could be appropriate. However, these 
observations were not confirmed by other groups (59, 
66), so the task of pertinently adjudicating risk when 
a patient is diagnosed with dnDSA remains challenging. 
Furthermore, some consider it advisable to perform 
histological evaluation when dnDSA are detected80, 
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although the absence of an effective treatment for 
subclinical dnDSA hampers this recommendation.
 Immunoglobulin subclasses
Characterization of IgG subclasses has been per-
formed by a modified SAB assay in the research setting, 
since originally it only measured total IgG (pan -IgG)84. 
Lefaucheur et al.85 showed, in patients with DSA detect-
ed at 1 -year post -transplant, that acute AMR was mainly 
driven by IgG3 DSA, whereas subclinical AMR by IgG4 
DSA. Additionally, they demonstrated that IgG3 DSA 
was strongly and independently associated with allo-
graft failure. These results provide clues about the 
pathogenicity of certain DSA and the immune response 
ensued by them. Still, the complexity of studying IgG 
subclasses constrains the possibility of its application 
in the clinical setting.
 CONCLUSIONS
Laboratory assays for the study of HLA alloantibodies 
are crucial in kidney transplantation and have evolved 
greatly, from cell -based crossmatches to SPI. Although 
most information added by these new assays is valuable, 
its clinical relevance is not always unequivocal, so they 
should be discussed in an integrated manner between 
HLA laboratory experts and clinicians, in order to fully 
encompass each test’s sensitivity and limitations. As such, 
the stratification of preformed DSA risk demands this 
concerted effort, to secure a correct identification of DSA 
and a meaningful assessment of the clinical implications 
pertained by them. While the analysis of DSA character-
istics, as MFI or complement -binding ability, gives valu-
able information about the risk involved, it should be 
accompanied by a thorough evaluation of clinical data 
and the results of cell -based crossmatches. In the post-
-transplant setting, dnDSA screening should be individual-
ized according to the immunological risk of each patient, 
determined not only at transplant (e.g., sensitization 
status, epitope mismatch load), but also according to 
significant clinical events (e.g., rejection episodes, docu-
mented non -adherence) observed afterwards. The emer-
gence of dnDSA is, by itself, a risk factor for adverse out-
comes, still a comprehensive alloantibody characterization, 
as complement -binding ability, may allow in each case a 
more granular analysis of the risk posed by dnDSA, par-
ticularly if concurrent histological evaluation is obtained.
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